Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Paeds SAQsgenetics-dysmorphology-and-metabolism

Paeds SAQs · genetics-dysmorphology-and-metabolism

Mucopolysaccharidoses and oligosaccharidoses — formative SAQs

Formative SAQs on the mucopolysaccharidoses and oligosaccharidoses: recognising the coarse-facies phenotype with dysostosis multiplex, grouping the subtypes by stored substrate and the discriminating cornea-versus-intellect signs, confirming with a layered urine-and-enzyme-and-genotype workup, and matching the disease-modifying therapy to central-nervous-system involvement.

20 marks30 min1 min readVerification in progress

Target exams

RACP General PaediatricsRACP DWEMRCPCH Clinical
On this page
Study tools

Target exams

RACP General PaediatricsRACP DWEMRCPCH Clinical
Prompt
Mucopolysaccharidoses and oligosaccharidoses across infancy and childhood

Question 1 (10 marks)

A three-year-old boy who appeared normal at birth is referred for progressive coarsening of the facial features, persistent umbilical hernia, snoring, and slowing of speech. Examination reveals macroglossia, hepatosplenomegaly with the liver edge 4 cm below the costal margin, claw-hand deformity, and a thoracolumbar gibbus. A skeletal survey shows dysostosis multiplex. The cornea is clear and he is a boy. [1] [2]

(a) Give the most likely disorder family and the single most discriminating bedside feature pointing to the subtype, justifying why the clear cornea matters. (3 marks) [1]

(b) Outline the stepwise confirmatory investigation strategy, naming the first-line screening test, the confirmatory enzyme test, and the molecular test, and explain how the urinary glycosaminoglycan pattern is used. (4 marks) [1] [2]

(c) Explain why the treatment modality depends on whether the central nervous system is involved, naming the two principal disease-modifying options and the constraint on each. (3 marks) [2] [3]

Paediatrics Fellowship Pro

Continue reading

You have read the opening of this SAQ. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship library.

Sign in to continueSee pricing
References4ShowHide
  1. [1]Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford), 2011.PMID 22210669
  2. [2]Wraith JE. Mucopolysaccharidoses and mucolipidoses. Handb Clin Neurol, 2013.PMID 23622395
  3. [3]Muenzer J, Wraith JE, Beck M, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med, 2006.PMID 16912578
  4. [4]Gentner B, Tucci F, Galimberti S, et al. Hematopoietic stem- and progenitor-cell gene therapy for Hurler syndrome. N Engl J Med, 2021.PMID 34788506
Paediatrics Fellowship Pro

$29/ monthor $279 / year

The complete Paediatrics Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousMitochondrial diseasegenetics-dysmorphology-and-metabolismNextNeurofibromatosis type 1 and type 2 — formative SAQsgenetics-dysmorphology-and-metabolism